Selectively Targeting
Inflammation

Amagma was founded in 2019 by serial entrepreneurs Tillman Gerngross, Ph.D. and Leonard Zon, M.D., to develop novel antibody therapies targeting diseases resulting from the dysfunction of essential proteases and other enzymes. These targets have long been of interest to the biopharmaceutical industry, but, despite this, there remain significant unmet medical needs across the many inflammatory conditions caused by protease dysfunction.

We believe that antibodies hold the greatest potential to successfully address these needs and have built a proprietary platform that has enabled us to identify highly specific and differentiated inhibitory antibodies that we are advancing into preclinical development.

Amagma is a privately held company headquartered in Waltham, Massachusetts.

Leadership

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

Co-Founder, Chairman

Jennifer Dovey, Ph.D.

Jennifer Dovey, Ph.D.

Chief Scientific Officer

Allan Capili, Ph.D.

Allan Capili, Ph.D.

Biologics Lead

Nicholas Scarchilli

Nicholas Scarchilli

Chief Business Officer

Board of Directors

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

Co-Founder, Chairman

Phil Ferneau

Phil Ferneau

Board Member

Amy Shulman

Amy Shulman

Board Member

Leonard Zon, M.D.

Leonard Zon, M.D.

Co-founder and Board Observer